Sign in or create an account to add this stock to your watchlist.
About Synlogic (NASDAQ:SYBX)
Synlogic, Inc. a clinical-stage biopharmaceutical company, focuses on the discovery and development of synthetic biotic medicines to treat metabolic, inflammatory, and cancer diseases in the United States. Its lead therapeutic programs include SYNB1020, an oral therapy, which is in Phase I clinical trial for the treatment of patients with liver disease and hepatic encephalopathy, and urea cycle disorders; and SYNB1618, an oral therapy that is in Phase I/IIa clinical trial to treat phenylketonuria. The company is also involved in developing discovery-stage product candidates for inborn errors of metabolism, including maple syrup urine disease, isovaleric acidemia, and organic acidemias. It has a collaboration agreement with AbbVie S.à.r.l. to develop synthetic biotic medicines for the treatment of inflammatory bowel diseases; Ginkgo Bioworks to discover new living medicines to treat neurological and liver disorders. Synlogic, Inc. is headquartered in Cambridge, Massachusetts.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:SYBX
CUSIPN/A
Phone617-401-9975
Debt
Debt-to-Equity RatioN/A
Current Ratio18.24
Quick Ratio18.24
Price-To-Earnings
Trailing P/E Ratio-1.66
Forward P/E Ratio-3.88
P/E GrowthN/A
Sales & Book Value
Annual Sales$2.44 million
Price / Sales78.04
Cash FlowN/A
Price / CashN/A
Book Value$6.59 per share
Price / Book1.48
Profitability
EPS (Most Recent Fiscal Year)($5.88)
Net Income$-40,370,000.00
Net MarginsN/A
Return on Equity-49.62%
Return on Assets-44.73%
Miscellaneous
Employees63
Outstanding Shares19,550,000
Synlogic (NASDAQ:SYBX) Frequently Asked Questions
What is Synlogic's stock symbol?
Synlogic trades on the NASDAQ under the ticker symbol "SYBX."
When did Synlogic's stock split? How did Synlogic's stock split work?
Synlogic's stock reverse split before market open on Monday, August 28th 2017. The 1-7 reverse split was announced on Friday, August 25th 2017. The number of shares owned by shareholders was adjusted after the market closes on Friday, August 25th 2017. An investor that had 100 shares of Synlogic stock prior to the reverse split would have 14 shares after the split.
How were Synlogic's earnings last quarter?
Synlogic Inc (NASDAQ:SYBX) issued its quarterly earnings results on Tuesday, May, 15th. The biotechnology company reported ($0.55) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.73) by $0.18. The biotechnology company had revenue of $0.35 million for the quarter, compared to the consensus estimate of $0.21 million. View Synlogic's Earnings History.
When is Synlogic's next earnings date?
What price target have analysts set for SYBX?
4 Wall Street analysts have issued 12 month price targets for Synlogic's shares. Their predictions range from $15.00 to $25.00. On average, they anticipate Synlogic's share price to reach $20.00 in the next year. View Analyst Ratings for Synlogic.
What are Wall Street analysts saying about Synlogic stock?
Here are some recent quotes from research analysts about Synlogic stock:
- 1. According to Zacks Investment Research, "Synlogic, Inc. engaged in the development of a novel class of living Synthetic Biotic(TM) medicines based on its proprietary drug discovery and development platform. The company's pipeline includes Synthetic Biotic medicines for the treatment of rare genetic diseases such as Urea Cycle Disorder and Phenylketonuria. In addition, the company is leveraging the broad potential of its platform to create Synthetic Biotic medicines for the treatment of other diseases, such as liver disease, inflammatory and immune disorders and cancer. It is collaborating with AbbVie to develop Synthetic Biotic-based treatments for inflammatory bowel disease. Synlogic Inc., formerly known as Mirna Therapeutics Inc., is based in Cambridge, Massachusetts. " (5/22/2018)
- 2. HC Wainwright analysts commented, "Shares When Financing and Leadership Gaps Filled Stock Data 03/16/2018 Price $1.98 Exchange NASDAQ Price Target $4.00 52-Week High $3.50 52-Week Low $1.60 Enterprise Value (M) $149.2 Market Cap (M) $110 Shares Outstanding (M) 55.9 3 Month Avg Volume 501,177 Short Interest (M) 2.74 Balance Sheet Metrics Cash (M) $21.2 Total Debt (M) $60.0 Total Cash/Share $0.38 EPS Diluted Full Year – Dec 2017A 2018E 2019E 1Q 0.91 (0.22) — 2Q (0.23) (0.18) — 3Q (0.18) (0.17) — 4Q (0.29) (0.16) — FY 0.21 (0.73) (0.39) Revenue ($M) Full Year – Dec 2017A 2018E 2019E 1Q 29.5 10.6 — 2Q 8.7 11.9 — 3Q 11.3 13.1 — 4Q 12.5 14.6 — FY 62.0 50.2 73.3 4 3.5 3 2.5 2 1.5 MAR- 17 J UL- 17 NOV- 17 MAR- 18 4 3 2 1 0 Vol. (mil) Price Another solid Belbuca growth quarter; expect near-term CEO and recapitalization." (3/19/2018)
Are investors shorting Synlogic?
Synlogic saw a decline in short interest in the month of April. As of April 13th, there was short interest totalling 539,697 shares, a decline of 43.5% from the March 30th total of 955,244 shares. Based on an average daily volume of 96,890 shares, the short-interest ratio is currently 5.6 days. Approximately 4.0% of the shares of the company are short sold.
Who are some of Synlogic's key competitors?
Some companies that are related to Synlogic include Vectura Group (VEGPF), GlycoMimetics (GLYC), Homology Medicines (FIXX), Arcus Biosciences (RCUS), CymaBay Therapeutics (CBAY), Dova Pharmaceuticals (DOVA), ANI Pharmaceuticals Inc Common Stock (ANIP), Dicerna Pharmaceuticals (DRNA), Geron (GERN), BeyondSpring (BYSI), Five Prime Therapeutics (FPRX), Rigel Pharmaceuticals (RIGL), Lannett (LCI), Odonate Therapeutics (ODT) and Ziopharm Oncology (ZIOP).
Who are Synlogic's key executives?
Synlogic's management team includes the folowing people:
- Dr. José Carlos Gutierrez-Ramos, Pres, CEO & Director
- Mr. Paul Francis Miller Ph.D., Chief Scientific Officer
- Dr. Aoife M. Brennan MB, BCh, BAO, MMSc, Chief Medical Officer
- Prof. Timothy K. Lu, Co-Founder
- Dr. Dean A. Falb Ph.D., Co-Founder & CTO (Age 51)
Has Synlogic been receiving favorable news coverage?
Headlines about SYBX stock have trended somewhat positive this week, Accern reports. Accern identifies positive and negative media coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Synlogic earned a daily sentiment score of 0.12 on Accern's scale. They also assigned news stories about the biotechnology company an impact score of 48.22 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the immediate future.
Who are Synlogic's major shareholders?
Synlogic's stock is owned by many different of institutional and retail investors. Top institutional investors include NEA Management Company LLC (21.63%), Farallon Capital Management LLC (4.99%), Sofinnova Ventures Inc (2.94%), Artal Group S.A. (2.05%), Texas Treasury Safekeeping Trust Co. (0.53%) and Dimensional Fund Advisors LP (0.29%). View Institutional Ownership Trends for Synlogic.
Which institutional investors are selling Synlogic stock?
Which institutional investors are buying Synlogic stock?
SYBX stock was bought by a variety of institutional investors in the last quarter, including Farallon Capital Management LLC, Sofinnova Ventures Inc, NEA Management Company LLC, Texas Treasury Safekeeping Trust Co., Dimensional Fund Advisors LP, JBF Capital Inc., Tibra Equities Europe Ltd and Northern Trust Corp. View Insider Buying and Selling for Synlogic.
How do I buy shares of Synlogic?
Shares of SYBX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Synlogic's stock price today?
One share of SYBX stock can currently be purchased for approximately $9.74.
How big of a company is Synlogic?
Synlogic has a market capitalization of $193.38 million and generates $2.44 million in revenue each year. The biotechnology company earns $-40,370,000.00 in net income (profit) each year or ($5.88) on an earnings per share basis. Synlogic employs 63 workers across the globe.
How can I contact Synlogic?
Synlogic's mailing address is 301 Binney St. Suite 402, Cambridge MA, 02142. The biotechnology company can be reached via phone at 617-401-9975 or via email at [email protected]
MarketBeat Community Rating for Synlogic (SYBX)
MarketBeat's community ratings are surveys of what our community members think about Synlogic and other stocks. Vote "Outperform" if you believe SYBX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SYBX will underperform the S&P 500 over the long term. You may vote once every thirty days.
Synlogic (NASDAQ:SYBX) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
4 Wall Street analysts have issued ratings and price targets for Synlogic in the last 12 months. Their average twelve-month price target is $20.00, suggesting that the stock has a possible upside of 105.34%. The high price target for SYBX is $25.00 and the low price target for SYBX is $15.00. There are currently 4 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 3.00 | 3.00 | 2.75 | 2.50 |
| Ratings Breakdown: | 0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $20.00 | $20.00 | $18.75 | $19.50 |
| Price Target Upside: | 105.34% upside | 75.75% upside | 94.30% upside | 4.11% upside |
Synlogic (NASDAQ:SYBX) Consensus Price Target History
Synlogic (NASDAQ:SYBX) Analyst Ratings History
Show:
(Data available from 5/24/2016 forward)
Synlogic (NASDAQ:SYBX) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Synlogic (NASDAQ SYBX) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 23.30%
Institutional Ownership Percentage: 84.88%
Synlogic (NASDAQ SYBX) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 12/1/2016 | Jon Irvin | VP | Sell | 280 | $1.43 | $400.40 | 7,625 |  |
| 11/1/2016 | Jon Irvin | VP | Sell | 280 | $1.28 | $358.40 | 8,055 | |
| 10/11/2016 | Jon Irvin | VP | Sell | 150 | $1.83 | $274.50 | 8,335 | |
| 10/3/2016 | Jon Irvin | VP | Sell | 250 | $1.93 | $482.50 | 8,485 | |
| 10/6/2015 | Michael Powell | Director | Buy | 857,142 | $7.00 | $5,999,994.00 | | |
| 10/6/2015 | Pfizer Inc | major shareholder | Buy | 714,285 | $7.00 | $4,999,995.00 | 2,489,364 | |
(Data available from 1/1/2013 forward)
Synlogic (NASDAQ SYBX) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | Synlogic (SYBX) PT Set at $20.00 by HC Wainwright
www.americanbankingnews.com - May 22 at 9:45 AM |
| Zacks Investment Research Upgrades Synlogic (SYBX) to "Buy"
www.americanbankingnews.com - May 19 at 3:27 PM |
| $270,000.00 in Sales Expected for Synlogic (SYBX) This Quarter
www.americanbankingnews.com - May 19 at 3:39 AM |
| Q3 2018 EPS Estimates for Synlogic (SYBX) Boosted by Analyst
www.americanbankingnews.com - May 18 at 7:56 AM |
| Synlogic (SYBX) to Post Q2 2018 Earnings of ($0.49) Per Share, Wedbush Forecasts
www.americanbankingnews.com - May 18 at 7:04 AM |
| -$0.68 EPS Expected for Synlogic (SYBX) This Quarter
www.americanbankingnews.com - May 17 at 12:55 PM |
| Synlogic (SYBX) to Post Q2 2018 Earnings of ($0.50) Per Share, Leerink Swann Forecasts
www.americanbankingnews.com - May 17 at 6:44 AM |
| Synlogic (SYBX) Rating Lowered to Sell at Zacks Investment Research
www.americanbankingnews.com - May 16 at 11:04 AM |
| Synlogic (SYBX) Issues Earnings Results, Beats Expectations By $0.18 EPS
www.americanbankingnews.com - May 16 at 10:52 AM |
 | Synlogic beats by $0.18, beats on revenue
seekingalpha.com - May 15 at 10:18 AM |
 | Synlogic Reports First Quarter 2018 Financial Results and Provides Business Update
finance.yahoo.com - May 15 at 10:18 AM |
| HC Wainwright Analysts Give Synlogic (SYBX) a $20.00 Price Target
www.americanbankingnews.com - May 11 at 8:05 PM |
| Synlogic Announces Leadership Change
finance.yahoo.com - May 10 at 4:23 PM |
| Synlogic (SYBX) Given Average Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - May 9 at 3:28 AM |
| $210,000.00 in Sales Expected for Synlogic (SYBX) This Quarter
www.americanbankingnews.com - May 1 at 1:46 AM |
| Synlogic (SYBX) to Release Quarterly Earnings on Monday
www.americanbankingnews.com - April 30 at 12:16 PM |
| Synlogic (SYBX) Expected to Announce Earnings of -$0.75 Per Share
www.americanbankingnews.com - April 29 at 9:06 PM |
| Synlogic (SYBX) Sees Large Drop in Short Interest
www.americanbankingnews.com - April 29 at 3:13 AM |
| Synlogic (SYBX) Upgraded by ValuEngine to Sell
www.americanbankingnews.com - April 27 at 10:20 PM |
 | Synlogic (SYBX) Receives Fast-Track Designation for SYNB1618
www.streetinsider.com - April 25 at 4:27 PM |
| HC Wainwright Reiterates "Buy" Rating for Synlogic (SYBX)
www.americanbankingnews.com - April 17 at 7:39 AM |
| Zacks: Brokerages Anticipate Synlogic (SYBX) Will Announce Quarterly Sales of $210,000.00
www.americanbankingnews.com - April 14 at 1:47 AM |
| Zacks: Brokerages Anticipate Synlogic (SYBX) Will Announce Earnings of -$0.75 Per Share
www.americanbankingnews.com - April 12 at 11:14 PM |
| Q2 2018 EPS Estimates for Synlogic (SYBX) Boosted by Piper Jaffray
www.americanbankingnews.com - April 11 at 8:41 AM |
 | Just How Smart Is Smart Medicine? MIT Scientists Are About To Find Out.
www.forbes.com - April 10 at 4:17 PM |
| Synlogic (SYBX) vs. Viking Therapeutics (VKTX) Head-To-Head Analysis
www.americanbankingnews.com - April 10 at 9:16 AM |
| Synlogic's (SYBX) "Buy" Rating Reaffirmed at Piper Jaffray
www.americanbankingnews.com - April 9 at 11:35 AM |
| Synlogic Announces Registered Direct Offering of Common Stock
finance.yahoo.com - April 6 at 10:14 AM |
| Analysts Offer Predictions for Synlogic's Q1 2018 Earnings (SYBX)
www.americanbankingnews.com - April 4 at 7:32 AM |
| Synlogic (SYBX) Doses First Patient in Phase 1b/2a Trial of SYNB1020
www.streetinsider.com - April 3 at 10:01 AM |
| Synlogic Doses First Patient in Phase 1b/2a Trial of SYNB1020 for Treatment of Hyperammonemia in Patients with Cirrhosis
finance.yahoo.com - April 2 at 10:10 AM |
| Synlogic (SYBX) Presents At Needham And Company 17th Annual Healthcare Conference - Slideshow
seekingalpha.com - March 29 at 4:16 PM |
| Brokerages Expect Synlogic Inc (SYBX) Will Post Quarterly Sales of $240,000.00
www.americanbankingnews.com - March 29 at 10:20 AM |
| Synlogic Inc Forecasted to Earn FY2018 Earnings of ($2.35) Per Share (SYBX)
www.americanbankingnews.com - March 26 at 1:26 AM |
| Synlogic Inc (SYBX) to Post Q1 2018 Earnings of ($0.74) Per Share, Wedbush Forecasts
www.americanbankingnews.com - March 26 at 1:02 AM |
| Synlogic Inc Expected to Post Q1 2018 Earnings of ($0.63) Per Share (SYBX)
www.americanbankingnews.com - March 23 at 7:14 AM |
| Synlogic to Present at the 17th Annual Needham Healthcare Conference
finance.yahoo.com - March 21 at 4:11 PM |
| Synlogic Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Business Update
finance.yahoo.com - March 20 at 4:09 PM |
| Synlogic to Present Data at the American Association for Cancer Research 2018 Annual Meeting
finance.yahoo.com - March 20 at 9:54 AM |
| Synlogic Inc (SYBX) Receives Average Rating of "Hold" from Analysts
www.americanbankingnews.com - March 20 at 3:34 AM |
| Synlogic (SYBX) Receives New Coverage from Analysts at HC Wainwright
www.americanbankingnews.com - March 19 at 11:34 AM |
| Why Synlogic (SYBX) Might Surprise This Earnings Season
finance.yahoo.com - March 19 at 9:51 AM |
| Q1 2018 Earnings Forecast for Synlogic Inc (SYBX) Issued By Wedbush
www.americanbankingnews.com - March 16 at 7:56 AM |
| Synlogic Inc (SYBX) Expected to Earn FY2022 Earnings of ($1.17) Per Share
www.americanbankingnews.com - March 15 at 2:52 PM |
| Synlogic Presents Clinical and Preclinical Data from Synthetic Biotic™ Medicine Programs for Treatment of Inborn Errors of Metabolism at Annual Meeting of The Society for Inherited Metabolic Disorders
finance.yahoo.com - March 12 at 10:33 AM |
| $110,000.00 in Sales Expected for Synlogic Inc (SYBX) This Quarter
www.americanbankingnews.com - March 11 at 5:38 AM |
| Contrasting Synlogic (SYBX) and Auxilium Pharmaceuticals (AUXL)
www.americanbankingnews.com - March 10 at 4:17 PM |
| Synlogic Inc (SYBX) Given Consensus Rating of "Hold" by Brokerages
www.americanbankingnews.com - February 23 at 3:16 AM |
| Analysts Expect Synlogic Inc (SYBX) to Announce -$0.79 Earnings Per Share
www.americanbankingnews.com - February 21 at 1:28 AM |
| Changes to its Board of Directors: Oryzon revamps its Board with an expert in Biomedicine and Epigenetics in the US industry
finance.yahoo.com - February 20 at 9:15 AM |
Synlogic (NASDAQ:SYBX) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Synlogic (NASDAQ:SYBX) Income Statement, Balance Sheet and Cash Flow Statement
Synlogic (NASDAQ SYBX) Stock Chart for Thursday, May, 24, 2018
Loading chart…
